DUBLIN--(BUSINESS WIRE)--Sep 14, 2018--The "Cystic Fibrosis - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

Cystic Fibrosis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Cystic Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cystic Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 5, 29, 27, 60 and 30 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 2, 1, 10, 9 and 1 molecules, respectively.

Cystic Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered

Introduction Cystic Fibrosis - Overview Cystic Fibrosis - Therapeutics Development Cystic Fibrosis - Therapeutics Assessment Cystic Fibrosis - Companies Involved in Therapeutics Development Cystic Fibrosis - Drug Profiles Cystic Fibrosis - Dormant Projects Cystic Fibrosis - Discontinued Products Cystic Fibrosis - Product Development Milestones

Companies Featured

4D Molecular Therapeutics Inc Advanced Inhalation Therapies (AIT) Ltd Aridis Pharmaceuticals Inc Arrowhead Pharmaceuticals Inc AstraZeneca Plc Boehringer Ingelheim GmbH Celtaxsys Inc Chiesi Farmaceutici SpA Enterprise Therapeutics Ltd Errant Gene Therapeutics LLC ethris GmbH Evaxion Biotech ApS Galapagos NV Generation Bio Corp Idorsia Pharmaceutical Ltd Immun System IMS AB Insmed Inc Johnson & Johnson Kamada Ltd Kyorin Pharmaceutical Co Ltd Lamellar Biomedical Ltd Laurent Pharmaceuticals Inc Lexicon Pharmaceuticals Inc Microbion Corp Novabiotics Ltd Novartis AG Protalix BioTherapeutics Inc Proteostasis Therapeutics Inc Pulmatrix Inc Sequoia Sciences Inc Shire Plc SolAeroMed Inc Synovo GmbH Vanda Pharmaceuticals Inc and many more...

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/sdm3n9/cystic_fibrosis?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180914005387/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Respiratory Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/14/2018 11:40 AM/DISC: 09/14/2018 11:40 AM

http://www.businesswire.com/news/home/20180914005387/en